Private Advisor Group LLC Increases Stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Private Advisor Group LLC grew its position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) by 103.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 31,427 shares of the company’s stock after acquiring an additional 16,008 shares during the quarter. Private Advisor Group LLC’s holdings in Recursion Pharmaceuticals were worth $212,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Axxcess Wealth Management LLC raised its stake in shares of Recursion Pharmaceuticals by 4.3% in the third quarter. Axxcess Wealth Management LLC now owns 43,884 shares of the company’s stock valued at $289,000 after acquiring an additional 1,795 shares during the period. Wedmont Private Capital increased its stake in Recursion Pharmaceuticals by 10.6% in the 4th quarter. Wedmont Private Capital now owns 20,943 shares of the company’s stock worth $144,000 after buying an additional 2,000 shares during the period. Green Alpha Advisors LLC increased its stake in Recursion Pharmaceuticals by 3.6% in the 4th quarter. Green Alpha Advisors LLC now owns 67,145 shares of the company’s stock worth $454,000 after buying an additional 2,346 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in Recursion Pharmaceuticals by 5.3% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 52,530 shares of the company’s stock worth $346,000 after buying an additional 2,667 shares during the period. Finally, KBC Group NV increased its stake in Recursion Pharmaceuticals by 79.9% in the 3rd quarter. KBC Group NV now owns 7,602 shares of the company’s stock worth $50,000 after buying an additional 3,377 shares during the period. Hedge funds and other institutional investors own 89.06% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently commented on RXRX. Leerink Partners reduced their price target on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a “market perform” rating on the stock in a research note on Friday, February 28th. KeyCorp reduced their price target on shares of Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating on the stock in a research note on Wednesday, January 8th. Cowen reaffirmed a “hold” rating on shares of Recursion Pharmaceuticals in a research note on Friday, February 28th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $11.00 target price on shares of Recursion Pharmaceuticals in a report on Thursday, February 6th. Three research analysts have rated the stock with a hold rating and two have given a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $8.25.

Recursion Pharmaceuticals Stock Down 5.2 %

Shares of Recursion Pharmaceuticals stock opened at $6.24 on Friday. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.35 and a quick ratio of 4.35. Recursion Pharmaceuticals, Inc. has a 1 year low of $5.60 and a 1 year high of $12.36. The firm’s 50-day moving average is $7.65 and its two-hundred day moving average is $7.08. The stock has a market cap of $2.44 billion, a price-to-earnings ratio of -4.08 and a beta of 0.85.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its quarterly earnings results on Friday, February 28th. The company reported ($0.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.17). Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The firm had revenue of $4.60 million during the quarter, compared to the consensus estimate of $19.04 million. During the same quarter in the prior year, the business posted ($0.42) earnings per share. The firm’s quarterly revenue was down 57.8% on a year-over-year basis. As a group, research analysts expect that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current fiscal year.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.